Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.04 USD | -2.55% | -13.55% | +6.80% |
Financials (USD)
Sales 2024 * | 239K | Sales 2025 * | 8.8M | Capitalization | 167M |
---|---|---|---|---|---|
Net income 2024 * | -119M | Net income 2025 * | -147M | EV / Sales 2024 * | 76 x |
Net cash position 2024 * | 149M | Net cash position 2025 * | 136M | EV / Sales 2025 * | 3.56 x |
P/E ratio 2024 * |
-1.28
x | P/E ratio 2025 * |
-1.41
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.21% |
Latest transcript on Adverum Biotechnologies, Inc.
1 day | -2.55% | ||
1 week | -13.55% | ||
Current month | -17.28% | ||
1 month | -27.89% | ||
3 months | -60.39% | ||
6 months | -10.67% | ||
Current year | +6.80% |
Managers | Title | Age | Since |
---|---|---|---|
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Linda Rubinstein
DFI | Director of Finance/CFO | 58 | 22-12-11 |
Bill Tan
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Whitcup
BRD | Director/Board Member | 64 | 20-04-15 |
Clarence Machado
CHM | Chairman | 60 | 17-03-13 |
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 8.04 | -2.55% | 1,794,585 |
24-05-16 | 8.25 | -5.71% | 353,791 |
24-05-15 | 8.75 | -2.02% | 252,881 |
24-05-14 | 8.93 | -2.62% | 232,641 |
24-05-13 | 9.17 | -1.40% | 218,291 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.80% | 167M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ADVM Stock